GATA2 Deficiency

Mendelian MONDO:0042982 Pathograph 22 Show in embeddings browser hereditary disease

GATA2 deficiency is an autosomal dominant disorder of haematopoiesis and immunity caused by heterozygous germline loss-of-function variants in the GATA2 transcription factor. Affected individuals develop progressive cytopenia of monocytes, B lymphocytes, natural killer cells and dendritic cells, with susceptibility to disseminated nontuberculous mycobacterial infection, severe human papillomavirus disease and invasive fungal infection, together with a high lifetime risk of myelodysplastic syndrome and acute myeloid leukaemia, frequently in adolescence and frequently accompanied by monosomy 7. The condition has been described under several names that represent presentations of one disorder, including MonoMAC syndrome, dendritic cell-monocyte-B and NK lymphoid deficiency, Emberger syndrome and familial MDS/AML.

Ask OpenScientist

Ask a research question about GATA2 Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
18
Phenotypes
22
Pathograph
1
Genes
1
Medical Actions
1
Subtypes
1
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
GATA2 deficiency results from heterozygous germline GATA2 variants, including coding loss-of-function alleles and variants in the intron 5 +9.5 kb enhancer, transmitted as an autosomal dominant trait with incomplete penetrance and variable expressivity. A substantial minority of cases are de novo.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:34387894 SUPPORT Human Clinical
"GATA2 deficiency syndrome (G2DS) is a rare autosomal dominant genetic disease predisposing to a range of symptoms, of which myeloid malignancy and immunodeficiency including recurrent infections are most common."
States the autosomal dominant inheritance pattern and the two dominant clinical axes of the disorder.
PMID:36455197 SUPPORT Human Clinical
"Inherited or de novo germ line heterozygous mutations in the gene encoding the transcription factor GATA2 lead to its deficiency."
Establishes that both inherited and de novo heterozygous germline alleles cause the disorder.
◆

Subtypes

1
MonoMAC / DCML deficiency MONDO:0013607
GATA2 hgnc:4171 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in GATA2 (hgnc:4171). hgnc:4171 is a gene from the HUGO Gene Nomenclature Committee.
The presentation in which the mononuclear cytopenia and its infectious consequences dominate, named MonoMAC for the monocytopenia and mycobacterial infection that define it and DCML deficiency for the four depleted lineages: dendritic cell, monocyte, B lymphocyte and natural killer cell. It is curated as a presentation of this entry rather than as a separate disease because its mechanism, its pathophysiology nodes and its treatment are the ones this entry already models, and because one individual may express myeloid, lymphatic and infectious features either in sequence or at once.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency"
Names this presentation and the four-lineage deficiency that defines it as consequences of GATA2 haploinsufficiency, which is what makes it a presentation of the disease this entry models rather than a separate entity.
⚙

Pathophysiology

7
GATA2 Haploinsufficiency
Heterozygous null alleles, missense variants in the second zinc finger, and regulatory variants in the intron 5 +9.5 kb enhancer all reduce functional GATA2 dosage below the threshold required for hematopoietic stem and progenitor cell maintenance.
GATA2 hgnc:4171 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GATA2 (hgnc:4171). hgnc:4171 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Hematopoietic Stem and Progenitor Cell Depletion Reduced GATA2 dosage falls below the threshold needed to maintain stem and progenitor survival and self-renewal, so the compartment attrits over years.
Lymphatic Vascular Development Defect GATA2 is independently required in lymphatic endothelium for valve morphogenesis, so the same reduced dosage acts on a second tissue that is not haematopoietic.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency; familial myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML); and Emberger syndrome (primary..."
Names haploinsufficiency as the mechanism and enumerates the presentations it unifies.
Hematopoietic Stem and Progenitor Cell Depletion
Reduced GATA2 dosage impairs survival and self-renewal of hematopoietic stem and progenitor cells, producing a progressively hypocellular marrow with multilineage dysplasia.
Downstream
Mononuclear Cytopenia Loss of the shared multilineage progenitor removes the source of monocytes, B lymphocytes, natural killer cells and dendritic cells.
Clonal Evolution to Myeloid Malignancy A chronically stressed, hypocellular marrow under replicative pressure provides the substrate on which somatic second hits are selected.
Bone Marrow Hypocellularity Attrition of the stem and progenitor compartment is what the marrow registers as progressive hypocellularity with multilineage dysplasia.
Show evidence (2 references)
PMID:36455197 SUPPORT Human Clinical
"The bone marrow failure is typically characterized by hypocellularity."
Confirms the hypocellular marrow that follows progenitor depletion.
PMID:40138552 SUPPORT Model Organism
"Similar to what has been observed in patients, our models showed that GATA2 haploinsufficiency leads to B lymphopenia, monocytopenia, lethal bone marrow failure (BMF), myelodysplasia, and lymphoblastic leukemia."
Mouse models of GATA2 haploinsufficiency reproduce the marrow failure and cytopenias, supporting a dosage-dependent progenitor defect.
Mononuclear Cytopenia
Progressive loss of circulating monocytes, B lymphocytes, natural killer cells and dendritic cells is the characteristic peripheral blood signature of the disorder.
Downstream
Impaired Antimycobacterial and Antiviral Immunity Depletion of the monocyte, natural killer and dendritic cell compartments removes the effectors that control intracellular pathogens and papillomavirus.
Alveolar Macrophage Depletion Alveolar macrophages depend on continuous replacement from circulating monocytes, so the monocytopenia propagates directly into the lung.
Monocytopenia Monocytopenia is the peripheral blood finding this disease is most often recognised by, and the one the MonoMAC presentation is named for.
B Lymphocytopenia B lymphocytes are one of the four lineages that arise from the lost multilineage progenitor.
Natural Killer Cell Deficiency Natural killer cells are depleted from the same lost progenitor.
Show evidence (1 reference)
PMID:36455197 SUPPORT Human Clinical
"The clinical manifestations result from the loss of a multilineage progenitor that gives rise to B lymphocytes, monocytes, natural killer cells, and dendritic cells, leading to cytopenias of these lineages and subsequent infections."
Attributes the characteristic four-lineage cytopenia to loss of a shared multilineage progenitor.
Impaired Antimycobacterial and Antiviral Immunity
Loss of monocyte and natural killer cell compartments removes control of intracellular pathogens, producing disseminated nontuberculous mycobacterial infection, severe and refractory human papillomavirus disease, and invasive fungal infection.
Downstream
Disseminated Nontuberculous Mycobacterial Infection Loss of the monocyte compartment removes the control of intracellular mycobacteria, which is why mycobacterial infection in this disease is disseminated.
Severe Human Papillomavirus Disease Loss of natural killer and dendritic cell function removes the response that clears papillomavirus, so infection becomes extensive and refractory.
Invasive Fungal Infection The same monocyte and dendritic cell deficit permits invasive fungal disease.
Show evidence (1 reference)
PMID:36455197 SUPPORT Human Clinical
"This results in a constellation of clinical features including nontuberculous mycobacterial, bacterial, fungal, and human papillomavirus infections, lymphedema, pulmonary alveolar proteinosis, and myelodysplasia."
Lists the infectious consequences that follow the mononuclear cytopenia.
Alveolar Macrophage Depletion
Alveolar macrophages are continuously replenished from circulating monocytes. With the monocyte compartment depleted, that replenishment fails and surfactant clearance falls, producing pulmonary alveolar proteinosis and impaired gas transfer. The defect is one of macrophage supply rather than of macrophage signalling, which is what distinguishes it from the hereditary PAP caused by GM-CSF receptor defects. The cited sources here establish the monocyte-to-respiratory-disease link; they do not themselves address GM-CSF signalling.
alveolar macrophage CL:0000583 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves alveolar macrophage (CL:0000583). CL:0000583 is a cell type from the Cell Ontology.
Downstream
Pulmonary Alveolar Proteinosis Failure to replenish alveolar macrophages from circulating monocytes leaves surfactant uncleared, which accumulates in the alveoli.
Reduced Pulmonary Diffusing Capacity Alveolar filling impairs gas transfer, which is measured as a reduced diffusing capacity.
Show evidence (2 references)
PMID:40264496 SUPPORT Human Clinical
"The most common respiratory diseases are pulmonary alveolar proteinosis, recurrent respiratory tract infections, and pulmonary hypertension."
Establishes pulmonary alveolar proteinosis as the leading respiratory manifestation of the disorder.
PMID:40264496 SUPPORT Human Clinical
"This mutation is known to cause a decrease in haematopoietic stem cells and a decrease in monocytes, dendritic cells, NK cells, and B cells, leading to various diseases such as haematological, infectious, respiratory, and neurological diseases."
Links the monocyte deficit to the respiratory disease, the causal step this node encodes.
Clonal Evolution to Myeloid Malignancy
Marrow under replicative stress acquires secondary cytogenetic and somatic lesions, characteristically monosomy 7, trisomy 8 and ASXL1 mutation, driving transformation to myelodysplastic syndrome and acute myeloid leukaemia.
Downstream
Myelodysplastic Syndrome Accumulated cytogenetic and somatic lesions in the dysplastic marrow establish myelodysplastic syndrome, the commonest malignant outcome.
Acute Myeloid Leukemia Continued clonal evolution of the dysplastic clone progresses to acute myeloid leukaemia.
Show evidence (4 references)
PMID:36455197 SUPPORT Human Clinical
"The latter 3 malignancies often occur in the setting of monosomy 7, trisomy 8, and acquired mutations in ASXL1 or in STAG2."
Names the specific somatic second hits that accompany transformation, the lesions this node asserts.
PMID:38067298 SUPPORT Human Clinical
"Disease progression (GATA2-EB, n = 6) was associated with increased GATA2 mRNA levels, restored expression of the GATA2 target EZH2, and increased H3K27me3."
Molecular correlate of progression in pediatric GATA2 deficiency marrow, from a 57-patient biopsy series.
PMID:38067298 SUPPORT Human Clinical
"Taken together, our findings highlight the potential drivers of disease progression in GATA2 deficiency, particularly increased histone trimethylation and dysregulated apoptosis."
Summarises the two proposed drivers of transformation.
+ 1 more reference
Lymphatic Vascular Development Defect
GATA2 is required for lymphovenous and lymphatic valve development; reduced dosage produces primary lymphedema in a subset of patients, the feature that defines the Emberger presentation.
Downstream
Primary Lymphedema Failure of lymphatic and lymphovenous valve morphogenesis leaves lymph drainage incompetent, which presents as primary lymphedema.
Show evidence (4 references)
PMID:34387894 SUPPORT Human Clinical
"Apart from lymphedema in which haploinsufficiency seems necessary, the mutational requirements of the other less common G2DS phenotypes is still unclear."
Indicates that the lymphatic phenotype specifically requires true haploinsufficiency rather than any GATA2 variant class.
PMID:31582413 SUPPORT Model Organism
"GATA2 is necessary for the development of lymphatic valves and lymphovenous valves, and for the patterning of lymphatic vessels."
Directly supports the developmental requirement this node asserts, which the genotype-correlation quote above does not establish. Graded MODEL_ORGANISM because valve development and vessel patterning are organismal readouts and the paper establishes them in mice and embryos, not in culture.
PMID:31582413 SUPPORT Model Organism
"miR-126-/- embryos recapitulate the phenotypes of mice lacking GATA2."
The in vivo genetic evidence placing miR-126 downstream of GATA2 in lymphatic development.
+ 1 more reference
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for GATA2 Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

18
Blood 7
Monocytopenia Decreased total monocyte count HP:0012312 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Monocytopenia, annotated with Decreased total monocyte count (HP:0012312), qualified as course progressive. HP:0012312 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence of disease (P < .001)."
Establishes this cytopenia as a disease-associated finding in the NIH cohort.
B Lymphocytopenia Decreased total B cell count HP:0010976 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is B lymphocytopenia, annotated with Decreased total B cell count (HP:0010976), qualified as course progressive. HP:0010976 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence of disease (P < .001)."
Establishes this cytopenia as a disease-associated finding in the NIH cohort.
Natural Killer Cell Deficiency Reduced total natural killer cell count HP:0040218 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced total natural killer cell count (HP:0040218). HP:0040218 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence of disease (P < .001)."
Establishes this cytopenia as a disease-associated finding in the NIH cohort.
Bone Marrow Hypocellularity HP:0005528 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone marrow hypocellularity (HP:0005528). HP:0005528 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36455197 SUPPORT Human Clinical
"The bone marrow failure is typically characterized by hypocellularity."
Reports marrow hypocellularity as the characteristic finding.
Myelodysplastic Syndrome Myelodysplasia HP:0002863 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myelodysplasia (HP:0002863). HP:0002863 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34387894 SUPPORT Human Clinical
"For those that develop myeloid malignancy (75% of all carriers with G2DS disease symptoms), the median age of onset is 17 years (range 0-78 years) and myelodysplastic syndrome is the first diagnosis in 75% of these cases with acute myeloid leukemia in a further 9%."
Quantifies MDS as the commonest first malignant diagnosis and gives the adolescent median onset age.
Acute Myeloid Leukemia HP:0004808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acute myeloid leukemia (HP:0004808). HP:0004808 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34387894 SUPPORT Human Clinical
"For those that develop myeloid malignancy (75% of all carriers with G2DS disease symptoms), the median age of onset is 17 years (range 0-78 years) and myelodysplastic syndrome is the first diagnosis in 75% of these cases with acute myeloid leukemia in a further 9%."
Gives the proportion of carriers presenting first with AML.
Venous Thrombosis HP:0004936 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Venous thrombosis (HP:0004936). HP:0004936 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Cardiovascular 1
Pulmonary Arterial Hypertension HP:0002092 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary arterial hypertension (HP:0002092). HP:0002092 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Ear 1
Sensorineural Hearing Loss Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
Endocrine 1
Hypothyroidism HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Immune 4
Disseminated Nontuberculous Mycobacterial Infection Recurrent mycobacterial infections HP:0011274 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent mycobacterial infections (HP:0011274). HP:0011274 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
Severe Human Papillomavirus Disease Persistent human papillomavirus infection HP:0020114 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Persistent human papillomavirus infection (HP:0020114), qualified as temporality chronic. HP:0020114 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
Sequelae: Human Papillomavirus-Associated Tumors
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
Invasive Fungal Infection Recurrent fungal infections HP:0002841 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent fungal infections (HP:0002841). HP:0002841 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
Panniculitis HP:0012490 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Panniculitis (HP:0012490). HP:0012490 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Metabolism 1
Primary Lymphedema HP:0001004 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphedema (HP:0001004). HP:0001004 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
Respiratory 2
Reduced Pulmonary Diffusing Capacity Decreased DLCO HP:0045051 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased DLCO (HP:0045051). HP:0045051 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Pulmonary Alveolar Proteinosis Intraalveolar phospholipid accumulation HP:0006517 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary alveolar proteinosis, annotated with Intraalveolar phospholipid accumulation (HP:0006517). HP:0006517 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
Neoplasm 1
Human Papillomavirus-Associated Tumors Neoplasm HP:0002664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24227816 SUPPORT Human Clinical
"We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70%, disseminated mycobacterial 53%, and invasive fungal infections 16%), pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar proteinosis..."
Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
🧬

Genetic Associations

1
GATA2
Gene: GATA2 hgnc:4171 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GATA2 (hgnc:4171). hgnc:4171 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:24227816 SUPPORT Human Clinical
"Viral infections and lymphedema were more common in individuals with null mutations (P = .038 and P = .006, respectively)."
Supports a genotype-phenotype correlation in which null alleles drive the viral and lymphatic features.
PMID:34387894 SUPPORT Human Clinical
"All variant types appear to predispose to myeloid malignancy and immunodeficiency."
Indicates the malignant and immune risks are not restricted to one variant class, in contrast to the lymphatic phenotype.
💊

Medical Actions

1
Allogeneic Hematopoietic Stem Cell Transplantation
Action: hematopoietic cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic cell transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
Platform: Cell therapy
Allogeneic HSCT replaces the GATA2-haploinsufficient hematopoietic compartment and is the only intervention that reverses the marrow failure, immunodeficiency and malignant predisposition. Timing is the central clinical question: transplant before evolution to monosomy 7 or advanced MDS gives markedly better outcomes than salvage after transformation.
Mechanism Target:
Hematopoietic Stem and Progenitor Cell Depletion — Donor stem cells restore a hematopoietic compartment with two functional GATA2 alleles, correcting the progenitor deficit at its source.
Show evidence (5 references)
PMID:29412158 SUPPORT Human Clinical
"Allogeneic hematopoietic stem cell transplantation (HSCT) reverses the bone marrow failure syndrome due to GATA2 deficiency."
States that transplant reverses the marrow failure phenotype.
PMID:29412158 SUPPORT Human Clinical
"At a median follow-up of 24 months (range, 9 to 50), 19 of 22 patients were alive with reversal of the disease phenotype and correction of the myelodysplastic syndrome, including eradication of cytogenetic abnormalities."
Prospective outcome data for busulfan-based conditioning in 22 patients.
PMID:36455197 SUPPORT Human Clinical
"Allogeneic hematopoietic stem cell transplantation (HSCT) results in reversal of the phenotype."
Independent review confirming transplant as the definitive treatment.
+ 2 more references
{ }

Source YAML

click to show 
name: GATA2 Deficiency
creation_date: "2026-08-31T00:00:00Z"
description: >-
  GATA2 deficiency is an autosomal dominant disorder of haematopoiesis and
  immunity caused by heterozygous germline loss-of-function variants in the
  GATA2 transcription factor. Affected individuals develop progressive
  cytopenia of monocytes, B lymphocytes, natural killer cells and dendritic
  cells, with susceptibility to disseminated nontuberculous mycobacterial
  infection, severe human papillomavirus disease and invasive fungal
  infection, together with a high lifetime risk of myelodysplastic syndrome
  and acute myeloid leukaemia, frequently in adolescence and frequently
  accompanied by monosomy 7. The condition has been described under several
  names that represent presentations of one disorder, including MonoMAC
  syndrome, dendritic cell-monocyte-B and NK lymphoid deficiency, Emberger
  syndrome and familial MDS/AML.
category: Mendelian
parents:
- hereditary disease
synonyms:
- MonoMAC syndrome
- DCML deficiency
- dendritic cell, monocyte, B lymphocyte and natural killer lymphocyte deficiency
- immunodeficiency 21
- GATA2 haploinsufficiency
disease_term:
  preferred_term: GATA2 deficiency
  term:
    id: MONDO:0042982
    label: GATA2 deficiency with susceptibility to MDS/AML
has_subtypes:
- name: MonoMAC
  display_name: MonoMAC / DCML deficiency
  subtype_term:
    preferred_term: monocytopenia with susceptibility to infections
    term:
      id: MONDO:0013607
      label: monocytopenia with susceptibility to infections
  description: >-
    The presentation in which the mononuclear cytopenia and its infectious
    consequences dominate, named MonoMAC for the monocytopenia and mycobacterial
    infection that define it and DCML deficiency for the four depleted lineages:
    dendritic cell, monocyte, B lymphocyte and natural killer cell. It is curated
    as a presentation of this entry rather than as a separate disease because its
    mechanism, its pathophysiology nodes and its treatment are the ones this entry
    already models, and because one individual may express myeloid, lymphatic and
    infectious features either in sequence or at once.
  genes:
  - preferred_term: GATA2
    term:
      id: hgnc:4171
      label: GATA2
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies
      monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and
      natural killer (NK) lymphoid deficiency
    explanation: >-
      Names this presentation and the four-lineage deficiency that defines it as
      consequences of GATA2 haploinsufficiency, which is what makes it a
      presentation of the disease this entry models rather than a separate entity.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    GATA2 deficiency results from heterozygous germline GATA2 variants,
    including coding loss-of-function alleles and variants in the intron 5
    +9.5 kb enhancer, transmitted as an autosomal dominant trait with
    incomplete penetrance and variable expressivity. A substantial minority
    of cases are de novo.
  evidence:
  - reference: PMID:34387894
    reference_title: "GATA2 deficiency syndrome: A decade of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GATA2 deficiency syndrome (G2DS) is a rare autosomal dominant genetic
      disease predisposing to a range of symptoms, of which myeloid malignancy
      and immunodeficiency including recurrent infections are most common.
    explanation: >-
      States the autosomal dominant inheritance pattern and the two dominant
      clinical axes of the disorder.
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inherited or de novo germ line heterozygous mutations in the gene encoding
      the transcription factor GATA2 lead to its deficiency.
    explanation: >-
      Establishes that both inherited and de novo heterozygous germline alleles
      cause the disorder.
pathophysiology:
- name: GATA2 Haploinsufficiency
  biological_scale: MOLECULAR
  description: >-
    Heterozygous null alleles, missense variants in the second zinc finger,
    and regulatory variants in the intron 5 +9.5 kb enhancer all reduce
    functional GATA2 dosage below the threshold required for hematopoietic
    stem and progenitor cell maintenance.
  genes:
  - preferred_term: GATA2
    term:
      id: hgnc:4171
      label: GATA2
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Haploinsufficiency of the hematopoietic transcription factor GATA2
      underlies monocytopenia and mycobacterial infections; dendritic cell,
      monocyte, B, and natural killer (NK) lymphoid deficiency; familial
      myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML); and Emberger
      syndrome (primary lymphedema with MDS).
    explanation: >-
      Names haploinsufficiency as the mechanism and enumerates the presentations
      it unifies.
  downstream:
  - target: Hematopoietic Stem and Progenitor Cell Depletion
    description: >-
      Reduced GATA2 dosage falls below the threshold needed to maintain stem
      and progenitor survival and self-renewal, so the compartment attrits over
      years.
  - target: Lymphatic Vascular Development Defect
    description: >-
      GATA2 is independently required in lymphatic endothelium for valve
      morphogenesis, so the same reduced dosage acts on a second tissue that is
      not haematopoietic.
- name: Hematopoietic Stem and Progenitor Cell Depletion
  biological_scale: CELLULAR
  description: >-
    Reduced GATA2 dosage impairs survival and self-renewal of hematopoietic
    stem and progenitor cells, producing a progressively hypocellular marrow
    with multilineage dysplasia.
  evidence:
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The bone marrow failure is typically characterized by hypocellularity.
    explanation: >-
      Confirms the hypocellular marrow that follows progenitor depletion.
  - reference: PMID:40138552
    reference_title: "Hematological phenotypes in GATA2 deficiency syndrome arise from aging, maladaptation to proliferation, and somatic events."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Similar to what has been observed in patients, our models showed that
      GATA2 haploinsufficiency leads to B lymphopenia, monocytopenia, lethal
      bone marrow failure (BMF), myelodysplasia, and lymphoblastic leukemia.
    explanation: >-
      Mouse models of GATA2 haploinsufficiency reproduce the marrow failure and
      cytopenias, supporting a dosage-dependent progenitor defect.
  downstream:
  - target: Mononuclear Cytopenia
    description: >-
      Loss of the shared multilineage progenitor removes the source of
      monocytes, B lymphocytes, natural killer cells and dendritic cells.
  - target: Clonal Evolution to Myeloid Malignancy
    description: >-
      A chronically stressed, hypocellular marrow under replicative pressure
      provides the substrate on which somatic second hits are selected.
  - target: Bone Marrow Hypocellularity
    description: >-
      Attrition of the stem and progenitor compartment is what the marrow
      registers as progressive hypocellularity with multilineage dysplasia.
- name: Mononuclear Cytopenia
  biological_scale: ORGANISM
  description: >-
    Progressive loss of circulating monocytes, B lymphocytes, natural killer
    cells and dendritic cells is the characteristic peripheral blood
    signature of the disorder.
  evidence:
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical manifestations result from the loss of a multilineage
      progenitor that gives rise to B lymphocytes, monocytes, natural killer
      cells, and dendritic cells, leading to cytopenias of these lineages and
      subsequent infections.
    explanation: >-
      Attributes the characteristic four-lineage cytopenia to loss of a shared
      multilineage progenitor.
  downstream:
  - target: Impaired Antimycobacterial and Antiviral Immunity
    description: >-
      Depletion of the monocyte, natural killer and dendritic cell compartments
      removes the effectors that control intracellular pathogens and
      papillomavirus.
  - target: Alveolar Macrophage Depletion
    description: >-
      Alveolar macrophages depend on continuous replacement from circulating
      monocytes, so the monocytopenia propagates directly into the lung.
  - target: Monocytopenia
    description: >-
      Monocytopenia is the peripheral blood finding this disease is most often
      recognised by, and the one the MonoMAC presentation is named for.
  - target: B Lymphocytopenia
    description: >-
      B lymphocytes are one of the four lineages that arise from the lost
      multilineage progenitor.
  - target: Natural Killer Cell Deficiency
    description: >-
      Natural killer cells are depleted from the same lost progenitor.
- name: Impaired Antimycobacterial and Antiviral Immunity
  biological_scale: ORGANISM
  description: >-
    Loss of monocyte and natural killer cell compartments removes control of
    intracellular pathogens, producing disseminated nontuberculous
    mycobacterial infection, severe and refractory human papillomavirus
    disease, and invasive fungal infection.
  evidence:
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This results in a constellation of clinical features including
      nontuberculous mycobacterial, bacterial, fungal, and human papillomavirus
      infections, lymphedema, pulmonary alveolar proteinosis, and myelodysplasia.
    explanation: >-
      Lists the infectious consequences that follow the mononuclear cytopenia.
  downstream:
  - target: Disseminated Nontuberculous Mycobacterial Infection
    description: >-
      Loss of the monocyte compartment removes the control of intracellular
      mycobacteria, which is why mycobacterial infection in this disease is
      disseminated.
  - target: Severe Human Papillomavirus Disease
    description: >-
      Loss of natural killer and dendritic cell function removes the response
      that clears papillomavirus, so infection becomes extensive and refractory.
  - target: Invasive Fungal Infection
    description: >-
      The same monocyte and dendritic cell deficit permits invasive fungal
      disease.
- name: Alveolar Macrophage Depletion
  biological_scale: TISSUE
  description: >-
    Alveolar macrophages are continuously replenished from circulating
    monocytes. With the monocyte compartment depleted, that replenishment
    fails and surfactant clearance falls, producing pulmonary alveolar
    proteinosis and impaired gas transfer. The defect is one of macrophage
    supply rather than of macrophage signalling, which is what distinguishes
    it from the hereditary PAP caused by GM-CSF receptor defects. The cited
    sources here establish the monocyte-to-respiratory-disease link; they do
    not themselves address GM-CSF signalling.
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  evidence:
  - reference: PMID:40264496
    reference_title: "GATA2 Deficiency With Early-Onset and Progressive Interstitial Lung Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common respiratory diseases are pulmonary alveolar proteinosis,
      recurrent respiratory tract infections, and pulmonary hypertension.
    explanation: >-
      Establishes pulmonary alveolar proteinosis as the leading respiratory
      manifestation of the disorder.
  - reference: PMID:40264496
    reference_title: "GATA2 Deficiency With Early-Onset and Progressive Interstitial Lung Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This mutation is known to cause a decrease in haematopoietic stem cells and
      a decrease in monocytes, dendritic cells, NK cells, and B cells, leading to
      various diseases such as haematological, infectious, respiratory, and
      neurological diseases.
    explanation: >-
      Links the monocyte deficit to the respiratory disease, the causal step this
      node encodes.
  downstream:
  - target: Pulmonary Alveolar Proteinosis
    description: >-
      Failure to replenish alveolar macrophages from circulating monocytes leaves
      surfactant uncleared, which accumulates in the alveoli.
  - target: Reduced Pulmonary Diffusing Capacity
    description: >-
      Alveolar filling impairs gas transfer, which is measured as a reduced
      diffusing capacity.
- name: Clonal Evolution to Myeloid Malignancy
  biological_scale: CELLULAR
  description: >-
    Marrow under replicative stress acquires secondary cytogenetic and
    somatic lesions, characteristically monosomy 7, trisomy 8 and ASXL1
    mutation, driving transformation to myelodysplastic syndrome and acute
    myeloid leukaemia.
  evidence:
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The latter 3 malignancies often occur in the setting of monosomy 7,
      trisomy 8, and acquired mutations in ASXL1 or in STAG2.
    explanation: >-
      Names the specific somatic second hits that accompany transformation, the
      lesions this node asserts.
  - reference: PMID:38067298
    reference_title: "Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Disease progression (GATA2-EB, n = 6) was associated with increased GATA2
      mRNA levels, restored expression of the GATA2 target EZH2, and increased
      H3K27me3.
    explanation: >-
      Molecular correlate of progression in pediatric GATA2 deficiency marrow,
      from a 57-patient biopsy series.
  - reference: PMID:38067298
    reference_title: "Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Taken together, our findings highlight the potential drivers of disease
      progression in GATA2 deficiency, particularly increased histone
      trimethylation and dysregulated apoptosis.
    explanation: >-
      Summarises the two proposed drivers of transformation.
  - reference: PMID:38887897
    reference_title: "GATA2 heterozygosity causes an epigenetic feedback mechanism resulting in myeloid and erythroid dysplasia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These findings suggest that cell-intrinsic compensatory mechanisms, needed
      to obtain normal levels of Gata2b in heterozygous HSPCs to maintain their
      integrity, result in aberrant lineage differentiation, thereby representing
      a critical step in the predisposition to MDS.
    explanation: >-
      Zebrafish model showing the compensatory response to heterozygosity is
      itself the predisposing step toward MDS.
  downstream:
  - target: Myelodysplastic Syndrome
    description: >-
      Accumulated cytogenetic and somatic lesions in the dysplastic marrow
      establish myelodysplastic syndrome, the commonest malignant outcome.
  - target: Acute Myeloid Leukemia
    description: >-
      Continued clonal evolution of the dysplastic clone progresses to acute
      myeloid leukaemia.
- name: Lymphatic Vascular Development Defect
  biological_scale: TISSUE
  description: >-
    GATA2 is required for lymphovenous and lymphatic valve development;
    reduced dosage produces primary lymphedema in a subset of patients, the
    feature that defines the Emberger presentation.
  evidence:
  - reference: PMID:34387894
    reference_title: "GATA2 deficiency syndrome: A decade of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Apart from lymphedema in which haploinsufficiency seems necessary, the
      mutational requirements of the other less common G2DS phenotypes is still
      unclear.
    explanation: >-
      Indicates that the lymphatic phenotype specifically requires true
      haploinsufficiency rather than any GATA2 variant class.
  - reference: PMID:31582413
    reference_title: "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GATA2 is necessary for the development of lymphatic valves and lymphovenous
      valves, and for the patterning of lymphatic vessels.
    explanation: >-
      Directly supports the developmental requirement this node asserts, which the
      genotype-correlation quote above does not establish. Graded MODEL_ORGANISM
      because valve development and vessel patterning are organismal readouts and
      the paper establishes them in mice and embryos, not in culture.
  - reference: PMID:31582413
    reference_title: "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      miR-126-/- embryos recapitulate the phenotypes of mice lacking GATA2.
    explanation: >-
      The in vivo genetic evidence placing miR-126 downstream of GATA2 in
      lymphatic development.
  - reference: PMID:31582413
    reference_title: "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Primary human lymphatic endothelial cells (HLECs) lacking GATA2
      (HLECΔGATA2) have altered expression of claudin 5 and VE-cadherin, and
      blocking miR-126 activity in HLECs phenocopies these changes in expression.
    explanation: >-
      The junctional mechanism shown in human primary cells. Split from the in
      vivo items above so each carries the evidence_source of the work that
      produced it, rather than one grade spanning both halves of a mixed study.
  downstream:
  - target: Primary Lymphedema
    description: >-
      Failure of lymphatic and lymphovenous valve morphogenesis leaves lymph
      drainage incompetent, which presents as primary lymphedema.
phenotypes:
- category: Hematologic
  name: Monocytopenia
  description: >-
    Progressive loss of circulating monocytes is the most consistent
    peripheral blood abnormality and gives the MonoMAC presentation its name.
  phenotype_term:
    preferred_term: Monocytopenia
    term:
      id: HP:0012312
      label: Decreased total monocyte count
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence
      of disease (P < .001).
    explanation: >-
      Establishes this cytopenia as a disease-associated finding in the NIH cohort.
- category: Hematologic
  name: B Lymphocytopenia
  description: >-
    Circulating B lymphocytes decline in parallel with monocytes, contributing
    to impaired humoral responses.
  phenotype_term:
    preferred_term: B lymphocytopenia
    term:
      id: HP:0010976
      label: Decreased total B cell count
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence
      of disease (P < .001).
    explanation: >-
      Establishes this cytopenia as a disease-associated finding in the NIH cohort.
- category: Hematologic
  name: Natural Killer Cell Deficiency
  description: >-
    Natural killer cells, particularly the CD56-bright subset, are severely
    reduced, removing a principal defence against herpesviruses and
    papillomaviruses.
  phenotype_term:
    preferred_term: Reduced total natural killer cell count
    term:
      id: HP:0040218
      label: Reduced total natural killer cell count
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Monocytopenia, B, NK, and CD4 lymphocytopenia correlated with the presence
      of disease (P < .001).
    explanation: >-
      Establishes this cytopenia as a disease-associated finding in the NIH cohort.
- category: Hematologic
  name: Bone Marrow Hypocellularity
  description: >-
    The marrow is characteristically hypocellular with multilineage dysplasia
    and atypical megakaryocytes, often preceding overt malignancy.
  phenotype_term:
    preferred_term: Bone marrow hypocellularity
    term:
      id: HP:0005528
      label: Bone marrow hypocellularity
  evidence:
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The bone marrow failure is typically characterized by hypocellularity.
    explanation: Reports marrow hypocellularity as the characteristic finding.
- category: Neoplastic
  name: Myelodysplastic Syndrome
  description: >-
    Myelodysplastic syndrome is the commonest malignant outcome and frequently
    presents in adolescence, often with monosomy 7 or trisomy 8.
  phenotype_term:
    preferred_term: Myelodysplasia
    term:
      id: HP:0002863
      label: Myelodysplasia
  evidence:
  - reference: PMID:34387894
    reference_title: "GATA2 deficiency syndrome: A decade of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For those that develop myeloid malignancy (75% of all carriers with G2DS
      disease symptoms), the median age of onset is 17 years (range 0-78 years)
      and myelodysplastic syndrome is the first diagnosis in 75% of these cases
      with acute myeloid leukemia in a further 9%.
    explanation: >-
      Quantifies MDS as the commonest first malignant diagnosis and gives the
      adolescent median onset age.
- category: Neoplastic
  name: Acute Myeloid Leukemia
  description: >-
    Progression to acute myeloid leukaemia follows clonal evolution of the
    dysplastic marrow.
  phenotype_term:
    preferred_term: Acute myeloid leukemia
    term:
      id: HP:0004808
      label: Acute myeloid leukemia
  evidence:
  - reference: PMID:34387894
    reference_title: "GATA2 deficiency syndrome: A decade of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For those that develop myeloid malignancy (75% of all carriers with G2DS
      disease symptoms), the median age of onset is 17 years (range 0-78 years)
      and myelodysplastic syndrome is the first diagnosis in 75% of these cases
      with acute myeloid leukemia in a further 9%.
    explanation: >-
      Gives the proportion of carriers presenting first with AML.
- category: Immunologic
  name: Disseminated Nontuberculous Mycobacterial Infection
  description: >-
    Disseminated infection with nontuberculous mycobacteria, especially
    Mycobacterium avium complex, is the defining infectious presentation.
  phenotype_term:
    preferred_term: Recurrent mycobacterial infections
    term:
      id: HP:0011274
      label: Recurrent mycobacterial infections
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Immunologic
  name: Severe Human Papillomavirus Disease
  description: >-
    Extensive, refractory cutaneous and anogenital warts occur, with a
    substantial risk of progression to squamous cell carcinoma.
  phenotype_term:
    preferred_term: Persistent human papillomavirus infection
    term:
      id: HP:0020114
      label: Persistent human papillomavirus infection
    temporality: CHRONIC
  sequelae:
  - target: Human Papillomavirus-Associated Tumors
    description: >-
      Persistent papillomavirus infection that cannot be cleared progresses to
      squamous neoplasia.
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Immunologic
  name: Invasive Fungal Infection
  description: >-
    Invasive aspergillosis and disseminated histoplasmosis occur on the
    background of monocyte and dendritic cell loss.
  phenotype_term:
    preferred_term: Recurrent fungal infections
    term:
      id: HP:0002841
      label: Recurrent fungal infections
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Lymphatic
  name: Primary Lymphedema
  description: >-
    Lower limb primary lymphedema occurs in a subset of patients and defines
    the Emberger presentation.
  phenotype_term:
    preferred_term: Lymphedema
    term:
      id: HP:0001004
      label: Lymphedema
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Auditory
  name: Sensorineural Hearing Loss
  description: >-
    Congenital or early-onset sensorineural hearing impairment is a feature of
    the Emberger presentation.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequencies for this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Respiratory
  name: Reduced Pulmonary Diffusing Capacity
  description: >-
    Impaired gas transfer is the single most frequent finding in the largest
    GATA2 deficiency cohort, more common than the mycobacterial infection the
    disorder is better known for, and is often subclinical at detection.
  phenotype_term:
    preferred_term: Decreased DLCO
    term:
      id: HP:0045051
      label: Decreased DLCO
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Respiratory
  name: Pulmonary Alveolar Proteinosis
  description: >-
    Surfactant accumulates in the alveoli because monocyte-derived alveolar
    macrophages are not replenished. The mechanism is upstream of the GM-CSF
    receptor, unlike hereditary PAP, so the defect is macrophage supply rather
    than macrophage signalling.
  phenotype_term:
    preferred_term: Pulmonary alveolar proteinosis
    term:
      id: HP:0006517
      label: Intraalveolar phospholipid accumulation
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Respiratory
  name: Pulmonary Arterial Hypertension
  description: >-
    Pulmonary arterial hypertension occurs in a minority and may progress with
    interstitial lung disease.
  phenotype_term:
    preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Neoplastic
  name: Human Papillomavirus-Associated Tumors
  description: >-
    Persistent HPV infection progresses to squamous neoplasia in roughly a
    third of patients, a consequence of the natural killer and dendritic cell
    deficit rather than of the marrow failure.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Dermatologic
  name: Panniculitis
  description: >-
    Panniculitis is a recognised cutaneous manifestation, distinct from the
    HPV-driven warts.
  phenotype_term:
    preferred_term: Panniculitis
    term:
      id: HP:0012490
      label: Panniculitis
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Vascular
  name: Venous Thrombosis
  description: >-
    Venous thromboembolism occurs at a rate well above the population
    background and is not explained by the cytopenias.
  phenotype_term:
    preferred_term: Venous thrombosis
    term:
      id: HP:0004936
      label: Venous thrombosis
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
- category: Endocrine
  name: Hypothyroidism
  description: >-
    Hypothyroidism occurs in a minority and is worth screening for given how
    easily it is attributed elsewhere.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a broad spectrum of disease: hematologic (MDS 84%, AML 14%,
      chronic myelomonocytic leukemia 8%), infectious (severe viral 70%,
      disseminated mycobacterial 53%, and invasive fungal infections 16%),
      pulmonary (diffusion 79% and ventilatory defects 63%, pulmonary alveolar
      proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts
      53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%,
      Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%,
      lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and
      hypothyroidism 14%.
    explanation: >-
      Frequency of this feature in the 57-patient NIH GATA2 deficiency cohort.
genetic:
- name: GATA2
  notes: >-
    Heterozygous germline GATA2 variants cause the disorder. Three variant
    classes are recognised: coding null alleles (frameshift, nonsense,
    whole-gene deletion) acting by haploinsufficiency; missense alleles
    concentrated in the second zinc finger that impair sequence-specific DNA
    binding; and regulatory variants disrupting the intron 5 +9.5 kb enhancer.
    Null alleles are over-represented among patients with lymphedema and severe
    viral disease.
  gene_term:
    preferred_term: GATA2
    term:
      id: hgnc:4171
      label: GATA2
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:24227816
    reference_title: "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Viral infections and lymphedema were more common in individuals with null
      mutations (P = .038 and P = .006, respectively).
    explanation: >-
      Supports a genotype-phenotype correlation in which null alleles drive the
      viral and lymphatic features.
  - reference: PMID:34387894
    reference_title: "GATA2 deficiency syndrome: A decade of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All variant types appear to predispose to myeloid malignancy and
      immunodeficiency.
    explanation: >-
      Indicates the malignant and immune risks are not restricted to one variant
      class, in contrast to the lymphatic phenotype.
treatments:
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >-
    Allogeneic HSCT replaces the GATA2-haploinsufficient hematopoietic
    compartment and is the only intervention that reverses the marrow failure,
    immunodeficiency and malignant predisposition. Timing is the central
    clinical question: transplant before evolution to monosomy 7 or advanced
    MDS gives markedly better outcomes than salvage after transformation.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Hematopoietic Stem and Progenitor Cell Depletion
    description: >-
      Donor stem cells restore a hematopoietic compartment with two functional
      GATA2 alleles, correcting the progenitor deficit at its source.
  evidence:
  - reference: PMID:29412158
    reference_title: "Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Allogeneic hematopoietic stem cell transplantation (HSCT) reverses the bone
      marrow failure syndrome due to GATA2 deficiency.
    explanation: >-
      States that transplant reverses the marrow failure phenotype.
  - reference: PMID:29412158
    reference_title: "Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At a median follow-up of 24 months (range, 9 to 50), 19 of 22 patients were
      alive with reversal of the disease phenotype and correction of the
      myelodysplastic syndrome, including eradication of cytogenetic
      abnormalities.
    explanation: >-
      Prospective outcome data for busulfan-based conditioning in 22 patients.
  - reference: PMID:36455197
    reference_title: "The spectrum of GATA2 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Allogeneic hematopoietic stem cell transplantation (HSCT) results in
      reversal of the phenotype.
    explanation: >-
      Independent review confirming transplant as the definitive treatment.
  - reference: PMID:34244664
    reference_title: "Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Advanced disease and monosomy 7 (-7) were associated with worse outcome.
    explanation: >-
      Supports the timing claim in this treatment's description: outcomes are
      worse once disease has advanced or monosomy 7 has emerged.
  - reference: PMID:34244664
    reference_title: "Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data support considering HSCT early in the course of GATA2 deficiency in
      young individuals.
    explanation: >-
      The EWOG-MDS registry conclusion on transplant timing, from 65 transplanted
      children and adolescents.
datasets: []
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: GATA2 Deficiency · 2026-08-31T20:06:45Z · View source

Created kb/disorders/GATA2_Deficiency.yaml for MONDO:0042982, the parent GATA2 deficiency entity. The already-curated Deafness-Lymphedema-Leukemia_Syndrome — Emberger, MONDO:0013540 — describes itself as a presentation within this spectrum, so the parent entry was the gap. Six pathophysiology nodes: GATA2 haploinsufficiency, HSPC depletion, mononuclear cytopenia, impaired antimycobacterial and antiviral immunity, clonal evolution to myeloid malignancy, lymphatic vascular development defect. Eleven phenotypes, one genetic block, allogeneic HSCT as treatment. Deep research: falcon was requested but returned HTTP 403 for an invalid EDISON_API_KEY; the run fell back to claude_code via --fallback-provider, recorded in the report frontmatter as fell_back, requested_provider and provider_attempts. Report references validated 14 of 14 resolved, confabulation_rate 0.0. The report Term Validation section flagged five mislabelled HP CURIEs — for example it called HP:0005506 bone marrow hypocellularity when that ID is Chronic myelogenous leukemia — so no CURIE was taken from the report. All HP and HGNC bindings were resolved independently from cache/hp/terms.csv, cache/hgnc/terms.csv and exact-match OLS queries. Validated with just validate covering schema, terms and references, 22 of 22 snippets verified, plus check-duplicate-keys and check-entity-refs.

Claude Code ▸
GATA2 Deficiency — Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 2026-08-31T20:00:33.783239

GATA2 Deficiency — Comprehensive Research Report

(Prepared for dismech curation. Per project convention, germline predisposition is treated separately from the somatic myeloid malignancies it predisposes to — see §6 and the note in §2. Basic genetics concepts (penetrance, mosaicism, haploinsufficiency mechanics) are not re-explained here per user context; the report leads with disease-specific claims and citations.)

1. Disease Information

Overview. GATA2 deficiency (GATA2 deficiency syndrome, G2DS) is an autosomal dominant disorder caused by heterozygous germline pathogenic variants in GATA2, a master hematopoietic zinc-finger transcription factor. A single genetic lesion produces a syndrome that was originally described as four apparently separate entities before their shared molecular cause was recognized: MonoMAC syndrome (monocytopenia with Mycobacterium avium complex infection), DCML deficiency (dendritic cell, monocyte, B- and NK-lymphoid deficiency), Emberger syndrome (primary lymphedema with MDS), and familial MDS/AML. Spinner et al. (Blood 2014, PMID:24227816) established that these are one disorder: "Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency; familial myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML); and Emberger syndrome." This is a curatorial lump call already made in the field — current nomenclature (Calvo & Hickstein, Blood 2023;141(13):1524–1532, PMID:36455197, "The spectrum of GATA2 deficiency syndrome") treats MonoMAC/DCML/Emberger/familial MDS-AML as phenotypic variation on one genetic lesion rather than genuinely distinct diseases, which should be reflected as has_subtypes or historical-synonym framing rather than separate dismech entries.

Key identifiers: - Gene: GATA2, HGNC:4173, OMIM 137295, chromosome 3q21.3 - OMIM phenotypes: Immunodeficiency 21 (MonoMAC) #614172; Emberger syndrome #614038; MDS predisposition (germline GATA2 mutation) #614286; AML predisposition citing GATA2 under #601626 - MONDO: MONDO:0013607 (GATA2 deficiency) - Orphanet: ORPHA:228423 (GATA2 deficiency spectrum) - ICD-10: D72.8 (other specified disorders of white blood cells) — no dedicated ICD-10/11 code exists - MeSH:* overlapping entries under primary immunodeficiency/MDS headings; no single dedicated MeSH descriptor

Synonyms: MonoMAC syndrome; DCML deficiency; Emberger syndrome; familial MDS/AML with GATA2 mutation; NK cell deficiency (GATA2-related); MGN syndrome (monocytopenia and mycobacterial infection).

Evidence base: Predominantly aggregated disease-level cohort data — the NIH natural history cohort (Spinner 2014, n=57, PMID:24227816), a French/Belgian multicenter cohort of 79 patients (Haematologica), and registry-based pediatric HSCT series (EWOG-MDS, n=65) — supplemented by individual case reports for rarer manifestations (interstitial lung disease, Hodgkin lymphoma). This is not primarily an EHR-derived phenotype.

2. Etiology

Disease causal factor: Monogenic. Heterozygous germline pathogenic GATA2 variants are necessary and sufficient; there is no reported environmental or infectious primary cause. (Note the important genocopy distinction for dismech: somatic 3q26/MECOM rearrangements — inv(3)(q21q26), t(3;3)(q21;q26) — hijack the distal GATA2 hematopoietic enhancer (G2DHE) to drive EVI1 overexpression while silencing GATA2 on the rearranged allele in sporadic AML; this is a somatic leukemia mechanism that convergently reduces GATA2 dosage and should NOT be modeled as the same pathophysiology node as germline GATA2 deficiency, even though both produce "GATA2 haploinsufficiency" biochemically. (Atlas Genet Cytogenet Oncol Haematol; Blood 2020;136(2):224, "Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.")

Genetic risk factors: - ~50% de novo variants; remainder inherited from an affected or (rarely) mosaic/asymptomatic parent (Homan et al., Hum Mutat 2021, PMID:34387894, "GATA2 deficiency syndrome: A decade of discovery" — confirms de novo variants in "24 individuals... among over 480 individuals with germline GATA2 pathogenic or likely pathogenic variants" in the aggregate literature). - Variant classes: (1) missense variants clustering in the C-terminal zinc finger (ZF2) DNA-binding domain, notably the recurrent hotspot R396Q; (2) null variants (nonsense, frameshift, splice-site, whole-gene deletion); (3) ~10% noncoding variants disrupting the intron-4 −77/+9.5-equivalent human enhancer (the "EBOX-GATA-ETS" element) or the distal hematopoietic enhancer region, causing regulatory haploinsufficiency without coding change (PDQ GATA2 Deficiency Syndrome, NCBI Bookshelf NBK606140). - No pathogenic GATA2 variants are present in gnomAD population databases, consistent with high penetrance and reproductive/somatic selection against germline carriage in the general population. - Genotype-phenotype correlation: null variants associate more strongly with viral infection susceptibility and lymphedema than missense variants (Spinner 2014, PMID:24227816); the PDQ summary states lymphedema specifically "is associated with GATA2 null pathogenic variants."

Modifier/susceptibility factors — somatic events, not germline risk factors: Progression to MDS/AML is driven by acquired somatic lesions superimposed on the germline haploinsufficient marrow: monosomy 7 (70–80% of pediatric MDS cases, 20–40% of adult cases), trisomy 8 (20–40% of adults), der(1;7) translocation, and somatic mutations in ASXL1, STAG2, SETBP1, and RUNX1. STAG2 mutation frequency and trisomy 8 both increase with age (PDQ summary; Blood 2023 review).

Protective factors: None specific to germline variant type are established. No population-level protective allele has been reported (consistent with gnomAD absence of the pathogenic alleles).

Environmental risk modifiers / gene-environment interaction: Not a primary environmental disease. The immunodeficiency component determines which pathogens cause disease (nontuberculous mycobacteria, HPV, EBV, fungi) rather than environmental exposure causing the underlying lesion — this is host-susceptibility, not classic gene-environment interaction.

3. Phenotypes

Frequencies below are from the NIH cohort (Spinner et al., Blood 2014, n=57, PMID:24227816) unless noted; onset/course descriptors are qualitative syntheses from the same source and the 2023 Blood review.

Phenotype Frequency HPO suggestion
Myelodysplastic syndrome 84% (of those with hematologic disease); 75% of all symptomatic carriers develop myeloid malignancy overall HP:0002863 Myelodysplasia
Acute myeloid leukemia 14% HP:0004808 Acute myeloid leukemia
Chronic myelomonocytic leukemia 8% HP:0032223 (CMML term if bound; else NCIT)
Monocytopenia Near-universal (defining feature) HP:0001099 Monocytopenia
B-lymphopenia Near-universal HP:0010976 B lymphocytopenia
NK-lymphopenia / NK cell deficiency Near-universal, with impaired NK cytotoxicity HP:0040218 Natural killer cell deficiency (or closest HPO)
Dendritic cell deficiency Near-universal (defining "DCML" feature) free-text / immunophenotype, no dedicated HPO
Severe viral infections (HSV, VZV, EBV, HPV) 70% HP:0002960 Recurrent viral infections
Disseminated nontuberculous mycobacterial infection 53% HP:0032101 (Recurrent atypical mycobacterial infections, if available)
Invasive fungal infection 16% HP:0002090 (recurrent fungal infection group)
Diffusion defect (lung) 79% HP:0006536 Reduced DLCO
Ventilatory defect 63% HP:0002088 Abnormal lung function
Pulmonary alveolar proteinosis 18% (up to ~50% of adults in some series) HP:0006517 Pulmonary alveolar proteinosis
Pulmonary arterial hypertension 9% HP:0002092 Pulmonary hypertension
Warts (cutaneous/anogenital HPV) 53% HP:0200043 Verrucae
HPV-positive tumors (cervical/anal/vulvar dysplasia and carcinoma) 35% HP:0012125 (HPV-related neoplasia; or map via NCIT)
Panniculitis 30% HP:0012286 Panniculitis
EBV-positive tumors 4% (includes reported Hodgkin lymphoma cases) —
Sensorineural hearing loss (congenital) 76% in some series; part of constitutional ~50% cluster HP:0000407 Sensorineural hearing loss
Lymphedema 11% (up to ~30% in other cohorts) HP:0001004 Lymphedema
Venous thrombosis 25% HP:0004936 Venous thrombosis
Miscarriage 33% (women of reproductive age) HP:0005268 Recurrent miscarriage
Hypothyroidism 14% HP:0000821 Hypothyroidism
Hypocellular/dysplastic bone marrow with atypical megakaryocytes 92% (bone marrow finding) HP:0005506 (bone marrow hypocellularity)
Inverted CD4:CD8 T-cell ratio Common —
Hydrocele, urogenital malformation Part of constitutional cluster (~50%) HP:0000034 Hydrocele; relevant UGT terms
ADHD-spectrum disorders Reported in constitutional cluster HP:0007018 Attention deficit hyperactivity disorder

Onset/course: Median age of clinical onset ~18–20 years (range 0–78), with the constellation typically emerging in late childhood through early adulthood rather than infancy — pediatric presentation is usually cytopenia/MDS or infection-driven rather than the constitutional (deafness/lymphedema) features, which are congenital but often noted retrospectively. Median age of myeloid neoplasm diagnosis is bimodal — ~12 years in pediatric-onset disease vs. ~35 years in adult-onset (PDQ NBK606140) — a distinction directly relevant to the dismech pediatric-framing convention: pediatric GATA2-MDS is disproportionately monosomy-7-driven (70–80% vs. 20–40% in adults) and behaves as a more aggressive, faster-progressing entity than adult-onset GATA2-MDS, arguing for treating pediatric vs. adult progression as distinguishable progression phases rather than a single undifferentiated course. Course is progressive and highly variable in tempo, even within families sharing an identical variant — some carriers remain asymptomatic lifelong. Lifetime penetrance is estimated at >80% by age 60 across the aggregate literature (~90% cited in some cohorts).

Quality of life: Not separately quantified with EQ-5D/SF-36 instruments in the literature identified; QoL burden is described narratively (chronic infection burden, HSCT-related morbidity, malignancy anxiety) rather than measured with standardized instruments.

4. Genetic/Molecular Information

Causal gene: GATA2 (HGNC:4173, NCBI Gene 2624, OMIM *137295), chromosome 3q21.3. Six zinc-finger-transcription-factor exons; two zinc fingers (ZF1 N-terminal, ZF2 C-terminal DNA-binding).

Variant classification and type: - Missense — the single largest reported class; in one series "19 different missense mutations were identified in 24 probands and 14 relatives (46%)." Cluster predominantly in ZF2. Recurrent hotspot p.R396Q is the subject of a dedicated 2024/2025 knock-in mouse model (below). - Null variants — nonsense, frameshift, canonical splice-site, whole-gene deletion, and even some synonymous variants shown to disrupt splicing. - Regulatory/noncoding — ~10% of cases: point substitutions or small indels in the intron-4 enhancer element (variously termed the −77/G2DHE/"EBOX-GATA-ETS" enhancer, human ortholog of the mouse +9.5 kb enhancer), and tandem duplications. - Functional impact category: predominantly loss-of-function / haploinsufficiency; ZF2 missense variants can also act as partial loss-of-function or, in some reports, weakly dominant-negative on DNA binding, but there is no established gain-of-function class in the germline deficiency syndrome (contrast with somatic GATA2 zinc-finger mutations reported in a minority of AML, which is a distinct oncogenic context, not germline deficiency).

Population frequency: Pathogenic GATA2 variants are absent from gnomAD — consistent with high penetrance for severe, reproductively/medically consequential disease and largely de novo/small-pedigree transmission rather than population-level carrier frequency.

Somatic (acquired) lesions on the germline background — the genetic path to MDS/AML: - Monosomy 7: 70–80% of pediatric GATA2-MDS; 20–40% of adult cases; in the original NIH cohort 16% had monosomy 7 and 24% trisomy 8 at any point, rising with disease evolution. - der(1;7) unbalanced translocation. - Somatic driver mutations: ASXL1, STAG2, SETBP1, RUNX1 (STAG2 and trisomy 8 frequency increase with age). - Clinical decision rule with direct diagnostic utility: "up to 72% of adolescents with an MDS diagnosis and monosomy 7 carry germline GATA2 pathogenic variants" (PDQ NBK606140) — monosomy-7 pediatric MDS should trigger germline GATA2 testing.

Distinguish from somatic 3q26/MECOM AML (see §2): In sporadic inv(3)/t(3;3) AML, a cis enhancer-hijacking event silences GATA2 on one allele while activating MECOM (EVI1) — mechanistically convergent on GATA2 haploinsufficiency but a different disease with a different genetic architecture (somatic structural rearrangement, no germline predisposition, distinct prognosis) and should not be curated under the germline GATA2 deficiency entry.

Epigenetics: A 2024 preprint/2025 published mechanistic study (PMID:38887897, "GATA2 heterozygosity causes an epigenetic feedback mechanism resulting in myeloid and erythroid dysplasia") proposes that GATA2 haploinsufficiency triggers a self-reinforcing epigenetic state (histone trimethylation changes reported in pediatric MDS marrow, PMC10705137) that entrenches dysplastic differentiation independent of additional mutation — relevant to modeling a biological_scale: MOLECULAR epigenetic node upstream of the cellular dysplasia node.

Chromosomal abnormalities: Not a primary chromosomal disorder; the relevant chromosomal abnormalities (monosomy 7, trisomy 8, der(1;7)) are all acquired somatic events in evolving marrow, not constitutional karyotype anomalies.

5. Environmental Information

GATA2 deficiency has no established environmental, dietary, or lifestyle causal factor — this is a purely monogenic host-susceptibility disorder. The "environmental" dimension of the disease is instead about which pathogens the immunodeficiency renders the host susceptible to, i.e., infectious triggers acting on a genetically primed innate/adaptive immune defect rather than independent causal exposures:

  • Nontuberculous mycobacteria (M. avium complex predominantly, also M. kansasii — PMC6489290 case report) — the defining infection of "MonoMAC."
  • Human papillomavirus — extensive cutaneous and anogenital disease, with malignant transformation risk (35% HPV-positive tumors).
  • Epstein-Barr virus — EBV-driven lymphoproliferative disease and reported Hodgkin lymphoma (PMC12719254, case report of siblings).
  • Herpesviruses (HSV, VZV) and disseminated fungal pathogens (Histoplasma capsulatum specifically implicated given the monocyte/macrophage defect).

No occupational, toxin, radiation, or dietary exposure is reported as a disease modifier in the identified literature; this section should largely be left unpopulated in a KB entry beyond the infectious-trigger framing above (which functionally belongs with the phenotype/pathophysiology sections as infection-driven complications of the immunodeficiency, not environmental[] causal exposures in the dismech schema sense).

6. Mechanism / Pathophysiology

Ordered causal chain

  1. A heterozygous germline GATA2 pathogenic variant (coding loss-of-function, ZF2 missense, or enhancer disruption) leads to ~50% reduction in functional GATA2 transcription-factor dosage in hematopoietic stem and progenitor cells (HSPCs) — GATA2 haploinsufficiency.
  2. Reduced GATA2 dosage disrupts the GATA2–FLI1–TAL1/SCL recursive regulatory triad and downstream target activation (e.g., HOXB4), which normally governs HSC specification, quiescence, and self-renewal — this results in impaired HSC homeostasis: aged/stressed Gata2-haploinsufficient HSCs show reduced self-renewal capacity and a myeloid-biased, proliferative shift rather than maintained quiescence (Blood Advances 2021, PMID pending verification; Gata2 haploinsufficiency mouse studies).
  3. Loss of the stem-cell "gatekeeper" function leads to a preleukemic state: single-cell transcriptomic studies of patient HSPCs (Blood Advances, "Sequencing of RNA in single cells...") show dysregulated apoptosis/cell-cycle/quiescence genes, increased erythroid/megakaryocytic priming, and decreased lymphoid priming — an early, cell-intrinsic bias toward the myeloid-dysplastic phenotype before any acquired somatic mutation.
  4. Concurrently, GATA2 haploinsufficiency in non-stem lineages results in disproportionate, near-complete loss of monocytes, B-cell precursors, NK cells, and circulating/tissue dendritic cells, with relative sparing of T cells — this is a lineage-selective, dosage-sensitive effect rather than pan-hematopoietic failure, consistent with GATA2's role in "activating pro-fate targets... in granulocyte-macrophage progenitors and... repressing alternative-fate genes... in dendritic-cell progenitors."
  5. The monocyte/dendritic-cell/NK deficiency leads to the clinical immunodeficiency phenotype: susceptibility to nontuberculous mycobacteria and Histoplasma (intramacrophagic pathogens, reflecting monocyte/macrophage dysfunction), HPV (reflecting NK/DC-mediated antiviral surveillance loss), and EBV/herpesvirus disease.
  6. In the lung, insufficient monocyte-derived alveolar macrophage reconstitution results in defective pulmonary surfactant clearance, manifesting as pulmonary alveolar proteinosis and diffusion/ventilatory defects — mechanistically analogous to (but genetically distinct from) CSF2RA-related hereditary PAP, since here the defect is upstream monocyte/macrophage supply rather than GM-CSF receptor signaling itself.
  7. Independently, in lymphatic endothelial cells, GATA2 haploinsufficiency disrupts direct transcriptional activation of PROX1 and FOXC2 (GATA2 binds regulatory elements in the PROX1 promoter) and of the GATA2 target miR-126, which is required for VE-cadherin/claudin-5 junctional integrity — this leads to dysmorphic, incompetent lymphatic and lymphovenous valves, producing the lymphedema phenotype in a subset (more penetrant with null variants) (PMC6857586, "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126"; Blood 2012;119(5):1283, original description of lymphedema-MDS GATA2 link).
  8. Over years, the haploinsufficient, epigenetically primed marrow acquires somatic second hits — most consequentially monosomy 7, but also trisomy 8, der(1;7), and mutations in ASXL1/STAG2/SETBP1/RUNX1 — which result in clonal evolution to myelodysplastic syndrome and, in a subset, transformation to AML or CMML. This step is the somatic-mutation-driven branch and is the appropriate place for a conforms_to link to a myeloid-malignancy/clonal-evolution module rather than modeling AML as germline-caused per se.
  9. Branch: in a minority, chronic marrow failure and dysplasia proceed to bone marrow failure independent of overt leukemic transformation, distinguishable histologically from idiopathic aplastic anemia by hypocellularity with reticulin fibrosis and atypical megakaryocytes in 92% of marrows (Blood 2015;125(1):56, "GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia").

Molecular pathways

GATA2 operates in a recursively autoregulated triad with FLI1 and TAL1/SCL, each binding the others' enhancers, at the apex of the HSC transcriptional network; it acts upstream of RUNX1 via the +23 enhancer (GATA2/FLI1/SCL complex assembly) and directly transactivates HOXB4. GO terms: GO:0030099 (myeloid cell differentiation), GO:0002520 (immune system development), GO:0060716 (labyrinthine layer blood vessel development – lymphatic analog), GO:0001945 (lymph vessel development).

Cellular processes and cell types

Affected cell types (CL terms): hematopoietic stem cell (CL:0000037), common myeloid progenitor, monocyte (CL:0000576), classical/plasmacytoid dendritic cell (CL:0000451/CL:0000784), natural killer cell (CL:0000623), B lymphocyte precursor (CL:0000816), alveolar macrophage (CL:0000583), lymphatic endothelial cell (CL:0002138).

Protein dysfunction

Predominantly loss-of-function at the protein level (reduced/absent functional protein from the mutant allele, or reduced transcription from a disrupted enhancer) rather than protein misfolding/aggregation. ZF2 missense variants impair sequence-specific DNA binding at GATA motifs without necessarily eliminating protein expression.

Advanced/omics findings (2023–2025)

  • Single-cell transcriptomics of patient HSPCs shows constrained gene correlation networks and myeloid-biased priming preceding overt MDS (Blood Advances, cited above).
  • A 2024/2025 Gata2^R396Q/+ knock-in mouse (Leukemia, 2024, "Modeling GATA2 deficiency in mice") recapitulates HSC functional decline, lineage-fate bias, and an accelerated-aging transcriptional signature in HSPCs, but — notably — does not spontaneously develop marked immunodeficiency or MDS/AML, indicating the germline lesion alone is necessary but not sufficient and that additional (likely somatic) drivers are required for full disease. This is directly relevant to a dismech HUMAN_MODEL_MISMATCH discussion: the mouse model recapitulates the preleukemic HSC phenotype (RECAPITULATES, MODERATE fidelity) but FAILS_TO_RECAPITULATE the leukemic/immunodeficiency endpoints.
  • A 2025 CRISPR-engineered isogenic human HSPC model (Leukemia, "CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs") shows mitotic dysfunction and premature cellular aging as a proximate mechanism linking haploinsufficiency to HSC exhaustion — an IN_VITRO-graded mechanistic link.
  • A 2025 study (Blood Cancer Journal, "GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC") reports allele-specific expression skewing toward the mutant allele in some patients, correlating with an HSC hyporesponsive/exhausted state — a genotype-severity modifier worth flagging as a mechanistic_hypotheses candidate (status: EMERGING) rather than established.

7. Anatomical Structures Affected

  • Organ/system level: Bone marrow/hematopoietic system (primary); immune system (monocyte/DC/NK/B compartments); lymphatic vasculature; lung (parenchyma/alveolar macrophage compartment); inner ear (cochlea, sensorineural); reproductive/urogenital system (miscarriage, urogenital malformation); thyroid (hypothyroidism); skin (warts, panniculitis); vascular system (venous thrombosis).
  • UBERON suggestions: bone marrow (UBERON:0002371), lymphatic vessel (UBERON:0001473), lymphovenous valve region, lung alveolus (UBERON:0002299), cochlea (UBERON:0000132), thyroid gland (UBERON:0002046).
  • Tissue/cell level: hematopoietic stem/progenitor compartment (bone marrow niche), lymphatic endothelium (valve-forming LECs specifically), alveolar macrophage/type II pneumocyte-adjacent monocyte-derived population, cochlear sensory epithelium (mechanism not detailed in identified literature — noted gap).
  • Subcellular: GO Cellular Component — nucleus (site of GATA2 transcriptional activity, GO:0005634); mitochondria implicated in the "increased mitochondrial mass/activity" preleukemic transition described above.
  • Localization/laterality: Lymphedema and hearing loss are typically bilateral; no lateralization pattern reported.

8. Temporal Development

  • Onset: Constitutional features (congenital sensorineural deafness, lymphedema when present, urogenital anomalies) are present from birth/early childhood but often recognized only retrospectively after a hematologic/infectious diagnosis. Symptomatic hematologic/immunologic disease has a median clinical onset ~18–20 years, with a bimodal split: pediatric-onset myeloid neoplasm (median age ~12) skews toward monosomy-7-driven, more aggressive MDS, while adult-onset disease (median age ~35) has a broader genetic and clinical spectrum.
  • Progression: Chronic, generally progressive — cytopenias evolve toward dysplasia, then MDS, with a subset transforming to AML/CMML. Course is highly variable in tempo, including intrafamilial variability among carriers of an identical variant; some remain lifelong asymptomatic (partial/incomplete penetrance).
  • Disease stages: Refractory cytopenia of childhood (RCC) → MDS with excess blasts → AML, tracked with standard pediatric/adult MDS staging (WHO/EWOG-MDS criteria) rather than a GATA2-specific staging system; monosomy-7 status is the dominant prognostic stratifier at each stage.
  • Remission/critical periods: No spontaneous remission pattern reported for the hematologic component; HSCT is the only means of durable remission/cure (see §12). The "critical period" for intervention is framed clinically as before irreversible organ damage (established pulmonary fibrosis/PAP, advanced MDS/monosomy 7) — i.e., earlier HSCT in patients with RCC and normal karyotype yields markedly better outcomes than delayed transplant after monosomy-7 evolution.

9. Inheritance and Population

  • Epidemiology: GATA2 deficiency accounts for ~7% of pediatric MDS and ~0.5% of adult MDS (PDQ NBK606140) — making it one of the most common single-gene predispositions to pediatric MDS specifically, though the disorder overall remains ultra-rare in the general population (no pathogenic alleles present in gnomAD).
  • Inheritance pattern: Autosomal dominant, de novo in roughly half of probands, otherwise inherited from an affected (or occasionally minimally symptomatic) parent.
  • Penetrance: Estimated >80% by age 60 in aggregate cohorts (some series cite ~90%); notably incomplete and age-dependent — a meaningful fraction of adult carriers remain hematologically/immunologically asymptomatic well into adulthood, which is directly relevant to genetic-counseling framing for asymptomatic relatives identified by cascade testing.
  • Expressivity: Markedly variable, including within families sharing an identical variant — siblings/parent-child pairs with the same mutation can present decades apart or with different organ-system emphasis (hematologic vs. lymphatic vs. pulmonary).
  • Germline mosaicism / founder effects: Not prominently reported as a recurring theme in the literature identified (most non-inherited cases are simple de novo, not parental mosaicism); no specific population founder variant has been described — pathogenic variants are private/family-specific, consistent with absence from gnomAD.
  • Consanguinity: Not implicated (autosomal dominant, not recessive).
  • Population demographics: No strong reported ethnic/geographic enrichment; case series are drawn from North American and European cohorts (NIH, French/Belgian) without a described differential prevalence by ancestry. Sex ratio is not reported as skewed; reproductive-age women show a notably high miscarriage rate (33%), relevant to counseling but not to differential incidence by sex.

10. Diagnostics

Genetic testing: - First-line: targeted GATA2 sequencing (including intron-4 enhancer region and copy-number analysis for whole-gene deletion) via NGS full-gene panels (e.g., Mayo Clinic Labs "GATAS" full gene analysis) — germline confirmation requires testing a non-hematopoietic tissue (cultured skin fibroblasts) when a hematologic malignancy is already present, to distinguish germline from somatic GATA2 involvement, and parental testing to establish de novo status. - Diagnostic trigger rule: monosomy 7 in a young MDS patient should prompt germline GATA2 testing (up to 72% of monosomy-7 pediatric MDS carries a germline GATA2 variant). - Testing is also indicated for family members being evaluated as potential HSCT donors, given the risk of transplanting a mutation-carrying graft (see §12).

Laboratory/immunophenotyping: Peripheral blood flow cytometry showing profound monocytopenia, B-lymphopenia, NK-lymphopenia, and dendritic cell deficiency with relative T-cell preservation and inverted CD4:CD8 ratio is a strong clinical pattern-recognition diagnostic clue predating genetic confirmation.

Bone marrow evaluation: Hypocellular marrow with reticulin fibrosis and atypical megakaryocytes (92% of cases) distinguishes GATA2-associated marrow failure from idiopathic aplastic anemia; cytogenetics (monosomy 7, trisomy 8) and somatic NGS panel (ASXL1, STAG2, SETBP1, RUNX1) for clonal evolution monitoring.

Imaging/functional testing: Pulmonary function testing (DLCO, spirometry) for the diffusion/ventilatory defects seen in the majority of patients; high-resolution CT for PAP or interstitial lung disease (a 2025 case report series documents "early-onset and progressive interstitial lung disease" as a GATA2 presentation, PMC12012643).

Differential diagnosis: Other inherited bone marrow failure/MDS-predisposition syndromes should be excluded or co-considered — SAMD9/SAMD9L syndromes, RUNX1 familial platelet disorder, ANKRD26-related thrombocytopenia, DDX41-related MDS/AML, SRP72-related BMF, telomere biology disorders (dyskeratosis congenita), Fanconi anemia, and ELANE-related severe congenital neutropenia — each has a distinct genetic/phenotypic signature but overlapping marrow-failure presentation.

Screening (established carriers): Periodic CBC/immune-status monitoring; yearly bone marrow evaluation with cytogenetics and somatic variant testing; HPV-related cancer screening (cervical/anal); avoidance of G-CSF (theoretical clonal-evolution risk).

11. Outcome/Prognosis

Malignancy risk: 75–80% lifetime risk of developing myeloid malignancy among symptomatic carriers; "80% of patients aged 40 having developed MDS/AML" in some cohort framings. MDS is the first hematologic diagnosis in 75% of malignancy cases, with AML developing in a further ~9–14% and CMML in ~8%.

Survival without treatment: Not separately quantified as an untreated natural-history survival curve in the identified literature (nearly all symptomatic patients proceed to HSCT); mortality risk is driven by both infectious complications (disseminated NTM, invasive fungal disease) pre-transplant and by malignant transformation.

Prognostic stratifiers: Karyotype at the time of transplant is the dominant prognostic factor — refractory cytopenia of childhood (RCC) with a normal karyotype carries excellent HSCT outcomes (DFS ~90%), while RCC with monosomy 7 is markedly worse (DFS ~67%); advanced MDS/AML at transplant and monosomy 7 both independently associate with worse post-HSCT outcome.

HSCT outcomes (pooled/registry data): - EWOG-MDS pediatric registry (n=65 with germline GATA2 mutation): 5-year overall survival 75%, disease-free survival 70%; treatment failure attributable roughly equally to non-relapse mortality and relapse (Bone Marrow Transplantation 2021, PMC8563415). - French/Belgian adult+pediatric series (n=67): long-term outcome analysis (British Journal of Haematology, cited above) — outcomes vary by disease stage at transplant, consistent with the karyotype-stratified pattern above. - Reported adult overall survival figures by indication in the PDQ synthesis: 54% (MDS/AML or immunodeficiency, general), 66% (children, MDS, monosomy 7), 88% (children, RCC, normal karyotype), 86% (young adults, immunodeficiency-predominant indication).

Complications: Chronic infection burden pre-transplant (NTM, fungal, HPV-driven neoplasia), post-HSCT graft-versus-host disease (not reported as increased over baseline in this population), and the specific transplant-related hazard of donor-derived MDS/AML when a related donor is an unrecognized mutation carrier — underscoring the requirement for donor germline testing in familial transplant.

Recovery potential: Successful HSCT reverses the cellular immunodeficiency phenotype (monocyte/B/NK reconstitution), resolves infection susceptibility, and eliminates the ongoing risk of leukemic transformation from the native marrow — i.e., HSCT is curative for the hematologic/immunologic disease, though it does not reverse pre-existing structural organ damage (established lymphedema, pulmonary fibrosis) accrued before transplant, which is the rationale for early referral.

12. Treatment

Curative therapy: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment and is recommended for essentially all symptomatic patients — nearly all individuals with GATA2-related MDS eventually undergo HSCT. NCIT: NCIT:C15431 (Hematopoietic Cell Transplantation) as therapeutic_modality: CELL_THERAPY. - Timing: should occur before irreversible organ damage — i.e., before advanced MDS/monosomy-7 evolution and before established pulmonary or lymphatic structural damage, given the strong karyotype-at-transplant prognostic effect described in §11. - Indications: recurrent infections, transfusion dependency, or clonal evolution to myeloid malignancy. - Conditioning: individually tailored; both myeloablative and reduced-intensity/nonmyeloablative regimens have been reported (a busulfan-based regimen is specifically described in one series, PMID:29412158); a 2025 registered trial (NCT05907746) is evaluating briquilimab (anti-CD117 antibody)–based conditioning as a lower-toxicity alternative — relevant as an emerging/experimental regimen. - Donor selection caveat: mandatory germline GATA2 testing of related potential donors, given reported donor-derived MDS/AML when an unrecognized carrier relative was used as donor.

Pharmacotherapy / supportive care: - Prophylactic azithromycin (empiric, for NTM prevention) — CHEBI azithromycin; treatment_term: NCIT:C15986 Pharmacotherapy, therapeutic_agent: azithromycin. - Antifungal prophylaxis in patients with severe cellular immunodeficiency. - Interferon-alfa has in vitro/small-series support for improving NK-cell cytotoxicity, considered for refractory HPV or herpesvirus disease. - HPV vaccination is empirically recommended early, given the marked HPV susceptibility (NCIT:C15346 Vaccination). - G-CSF is avoided due to theoretical clonal-evolution risk in a genetically primed marrow.

Experimental/advanced therapeutics (2025): - CRISPR-Cas9 allele-specific gene correction in autologous HSPCs using rAAV6-mediated homology-directed repair has been reported as a proof-of-concept therapeutic strategy (Molecular Therapy, 2025, PMID:40739756) — positions autologous gene-corrected HSCT as a prospective alternative to allogeneic transplant, avoiding GVHD/donor-search barriers; still preclinical/early-phase, not standard of care. - Briquilimab-conditioned HSCT trial (NCT05907746), ongoing.

No consensus clinical practice guideline yet exists for GATA2 deficiency management — surveillance and treatment intensity remain individually tailored, per the 2023 Blood review and the PMC10000430 clinical-spectrum review.

13. Prevention

  • Primary prevention: Not applicable to the germline lesion itself (no modifiable risk factor); HPV vaccination functions as primary prevention against the downstream HPV-driven malignancy risk specifically.
  • Secondary prevention/screening: Structured surveillance in known carriers — periodic CBC/immune monitoring, annual bone marrow evaluation with cytogenetics/NGS for clonal evolution, HPV-related cancer screening (cervical/anal cytology) — functions as early detection of transformation to enable earlier, better-outcome HSCT.
  • Genetic counseling: Autosomal dominant inheritance with incomplete, age-dependent penetrance and highly variable expressivity should be explicitly communicated to families — an asymptomatic parent may still be a carrier, and cascade testing of first-degree relatives (including potential HSCT donors) is clinically actionable. No formal prenatal/preimplantation genetic testing protocol specific to GATA2 was identified in the literature searched, though the general NGS-based testing infrastructure (used for other monogenic PGT indications) is technically applicable; this should be flagged as an inferred extrapolation, not a documented GATA2-specific practice.
  • Prophylaxis: Azithromycin (NTM) and antifungal prophylaxis in immunodeficient carriers function as tertiary/complication prevention rather than disease prevention per se.
  • Public health: No population screening program exists (ultra-rare, gnomAD-absent alleles); this is managed entirely through clinical/familial ascertainment, not newborn or population screening.

14. Other Species / Natural Disease

No naturally occurring GATA2-deficiency-like disease has been identified in this search in companion animals, livestock, or wildlife (no OMIA entry or veterinary case series located) — this section should record an explicit "not found" rather than a fabricated cross-species claim. This is consistent with the pattern that most engineered animal work on GATA2 is laboratory-model-driven (mouse, zebrafish) rather than a naturally arising veterinary phenocopy.

Orthology: Gata2 is highly conserved; mouse ortholog Gata2 (MGI:95662), zebrafish has two paralogs gata2a and gata2b (from a teleost genome duplication) with partially divergent functions (see §15).

15. Model Organisms

  • Mouse — full knockout: Gata2-null mice are embryonic lethal at E10.5 due to failure of definitive hematopoiesis, establishing GATA2 as essential (not merely modulatory) for HSC generation — this is a full-null lethality that cannot model the human heterozygous-viable disease directly.
  • Mouse — heterozygous/haploinsufficient models: Gata2^+/− and conditional (Vav-Cre;Gata2^fl/+) mice are viable and recapitulate HSC functional decline under proliferative/aging stress — reduced self-renewal, myeloid bias, and (in a 2025 Blood Advances study) leukemia arising specifically in the context of bone marrow failure with somatic aberrations, increased Myc-target expression, and genomic instability (PMID:40138552) — a RECAPITULATES/MODERATE-to-HIGH fidelity model for the preleukemic HSC phenotype specifically.
  • Mouse — Gata2^R396Q/+ knock-in (patient-hotspot variant): recapitulates aberrant lineage-fate decisions and an accelerated-HSC-aging transcriptional signature but does not spontaneously develop marked immunodeficiency or MDS/AML — explicitly noted by the authors as requiring "additional drivers" for full disease (Leukemia, 2024). This is a clean HUMAN_MODEL_MISMATCH candidate: model recapitulates the HSC-intrinsic lesion but fails to recapitulate the clinical leukemic/immunodeficient endpoint, implying non-cell-intrinsic or additional-somatic-hit requirements not yet captured by the germline mutation alone.
  • +9.5 enhancer mouse models: Deletion/mutation of the conserved Gata2 +9.5 kb enhancer disrupts adult HSC self-renewal and T-cell differentiation, modeling the human noncoding-enhancer-variant patient subset specifically (as opposed to coding variants).
  • Zebrafish: Two paralogs, gata2a and gata2b; gata2b is specifically required for hematopoietic stem/progenitor cell emergence from hemogenic endothelium. Complete loss of gata2b is nonlethal (unlike mouse full knockout) and produces neutropenia, making zebrafish a genetically tractable system for adult/definitive hematopoiesis phenotyping that mouse full-knockout lethality precludes. A dedicated zebrafish MonoMAC model (bioRxiv, "A zebrafish model for MonoMAC syndrome") identifies an earlier developmental role for gata2 in hemogenic-endothelium programming than previously appreciated in mammalian systems — a fidelity caveat, since this developmental-window emphasis may not map directly onto human postnatal-onset disease.
  • Human iPSC/CRISPR-engineered isogenic HSPC models (2025): Allele-specific CRISPR-Cas9 correction and CRISPR-engineered heterozygous-knockout human HSPC models directly recapitulate mitotic dysfunction and premature cellular aging (Leukemia, 2025) — the highest-fidelity in vitro human model currently reported, though still IN_VITRO rather than whole-organism.

Limitations across models: No model to date spontaneously reproduces the full human triad of (1) selective monocyte/DC/NK/B lymphoid deficiency, (2) lymphatic valve/lymphedema phenotype, and (3) progression to overt MDS/AML from a single germline lesion without additional engineered somatic hits — each model system captures a subset (HSC-intrinsic aging/exhaustion in mouse/human HSPC models; hemogenic-endothelium/HSPC-emergence biology in zebrafish; lymphatic valve morphogenesis in Gata2-conditional lymphatic-endothelial-specific mouse deletion) rather than the integrated clinical syndrome.

Summary of Suggested Ontology Bindings

Category Suggested terms
MONDO MONDO:0013607 (GATA2 deficiency)
Genes hgnc:4173 (GATA2)
Key HP terms HP:0001099 Monocytopenia; HP:0010976 B lymphocytopenia; HP:0002863 Myelodysplasia; HP:0004808 Acute myeloid leukemia; HP:0006517 Pulmonary alveolar proteinosis; HP:0001004 Lymphedema; HP:0000407 Sensorineural hearing loss; HP:0200043 Verrucae; HP:0002960 Recurrent viral infections; HP:0005268 Recurrent miscarriage; HP:0012286 Panniculitis; HP:0004936 Venous thrombosis
GO (biological process) GO:0030099 myeloid cell differentiation; GO:0001945 lymph vessel development; GO:0002520 immune system development
CL (cell types) CL:0000037 HSC; CL:0000576 monocyte; CL:0000451/CL:0000784 dendritic cell; CL:0000623 NK cell; CL:0000816 B lymphoblast; CL:0000583 alveolar macrophage; CL:0002138 lymphatic endothelial cell
UBERON UBERON:0002371 bone marrow; UBERON:0001473 lymphatic vessel; UBERON:0002299 lung alveolus; UBERON:0000132 cochlea
Treatment NCIT NCIT:C15431 Hematopoietic Cell Transplantation; NCIT:C15986 Pharmacotherapy; NCIT:C15346 Vaccination
Therapeutic agents (CHEBI) azithromycin

Key Sources

  • Spinner MA, et al. "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity." Blood. 2014;123(6):809–821. PMID:24227816.
  • Calvo KR, Hickstein DD. "The spectrum of GATA2 deficiency syndrome." Blood. 2023;141(13):1524–1532. PMID:36455197.
  • Homan CC, et al. "GATA2 deficiency syndrome: A decade of discovery." Hum Mutat. 2021. PMID:34387894.
  • GATA2 Deficiency Syndrome (PDQ®) — NCI/PDQ Cancer Information Summaries, NCBI Bookshelf NBK606140.
  • "GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia." Blood. 2015;125(1):56.
  • "Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema..." Blood. 2012;119(5):1283.
  • Hematopoietic stem cell transplantation in children and adolescents with GATA2-related MDS (EWOG-MDS registry). Bone Marrow Transplant. 2021. PMC8563415.
  • "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126." PMC6857586.
  • Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in AML. Blood. 2020;136(2):224.
  • "Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis." Leukemia. 2024.
  • "CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs." Leukemia. 2025.
  • "Treatment of GATA2 deficiency by allele-specific CRISPR-Cas9-directed gene correction in hematopoietic stem cells." Molecular Therapy. 2025. PMID:40739756.
  • "Hematological phenotypes in GATA2 deficiency syndrome arise from aging, maladaptation to proliferation, and somatic events." Blood Advances. 2025. PMID:40138552.
  • "GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome." Blood Cancer J. 2025.
  • OMIM #614172 (Immunodeficiency 21/MonoMAC), #614038 (Emberger syndrome), #614286 (MDS predisposition), *137295 (GATA2).
  • Orphanet ORPHA:228423; MONDO:0013607.

Note on verification status: Several PMIDs above were confirmed directly from PubMed search-result metadata; article content for OMIM entries and some full-text sources could not be directly fetched (403/404 responses) and their content here is reconstructed from search-result snippets — treat OMIM clinical-synopsis details as leads requiring direct OMIM confirmation before use in a KB evidence snippet, per dismech's exact-quote requirement.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 14
Resolved 14
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 14
On topic 13
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 49
Resolved 45
Unresolved (possible confabulation) 1
Obsolete 0
Unverifiable 3
Terms whose name was checked 7
Terms named correctly 0
Terms named as a different term 5
Terms whose name is worth a second look 2

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0032223 (1 mention) - the report calls it "CMML term if bound; else NCIT"; HP calls it Blood group
  • HP:0032101 (1 mention) - the report calls it "Recurrent atypical mycobacterial infections, if available"; HP calls it Unusual infection
  • HP:0002090 (1 mention) - the report calls it "recurrent fungal infection group"; HP calls it Pneumonia
  • HP:0012125 (1 mention) - the report calls it "HPV-related neoplasia; or map via NCIT"; HP calls it Prostate cancer
  • HP:0005506 (1 mention) - the report calls it "bone marrow hypocellularity"; HP calls it Chronic myelogenous leukemia

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

  • UBERON:0000132 (2 mentions) - UBERON does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • MONDO:0013607 (3 mentions) - the report calls it "GATA2 deficiency"; MONDO calls it monocytopenia with susceptibility to infections, and lists "immunodeficiency 21" among its other names
  • UBERON:0002371 (2 mentions) - the report calls it "UBERON suggestions: bone marrow"; UBERON calls it bone marrow**

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.